{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "69-year-old woman diagnosed with lung adenocarcinoma with bilateral lung metastases harboring an HER2 exon 20 insertion (p.Tyr772_Ala775Dup). Patient has type 2 diabetes, hypertension, high cholesterol, and obesity grade I.",
        "timestamp": "2019-12",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Lung adenocarcinoma",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "E11.9",
              "label": "Type 2 diabetes mellitus",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "I10",
              "label": "Hypertension",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "E78.0",
              "label": "High cholesterol",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "E66.01",
              "label": "Obesity grade I",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Received first-line treatment with four cycles of carboplatin (AUC5), pemetrexed (500 mg/m2), and pembrolizumab (200 mg) every 3 weeks, achieving a partial response.",
        "timestamp": "2019-12",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0007138",
              "dosage": "AUC5",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0876370",
              "dosage": "500 mg/m2",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C4049449",
              "dosage": "200 mg",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": "C0030705",
              "label": "Partial Response",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Stereotaxic lung radiotherapy delivered to the left lung lobe.",
        "timestamp": "2020-11",
        "clinical_data": {
          "procedures": [
            {
              "name": "Stereotactic body radiation therapy to lung (procedure)",
              "approach": "other",
              "date": null,
              "location": "left lung lobe",
              "performed_by": null,
              "outcome": null
            }
          ],
          "imaging": [
            {
              "type": "Radiotherapy",
              "body_part": "Lung",
              "modality": "other",
              "finding": null,
              "impression": null,
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Maintenance with pemetrexed and pembrolizumab (total of 20 cycles).",
        "timestamp": "2021-08",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0972734",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1663790",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "CT scan revealed progression in the lung.",
        "timestamp": "2021-08",
        "clinical_data": {
          "imaging": [
            {
              "type": "CT scan",
              "body_part": "lung",
              "modality": "CT",
              "finding": "progression"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Patient included in the phase 2 randomized DESTINY-Lung02 study with trastuzumab deruxtecan as a second-line therapy.",
        "timestamp": "2021-08",
        "clinical_data": {
          "medications": [
            {
              "drug": "C4721549",
              "indication": "C0006826"
            }
          ],
          "diagnoses": [
            {
              "code": "C0006826",
              "label": "Lung Cancer",
              "status": "active"
            }
          ],
          "procedures": [
            {
              "name": "C0524744",
              "outcome": "C0006826"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Treatment with trastuzumab deruxtecan (blinded dose 6.4 mg/kg or 5.4 mk/kg) every 3 weeks started after cardiac evaluation revealed no morphologic or functional alterations.",
        "timestamp": "2021-10",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1635969",
              "dosage": "6.4 mg/kg",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null
            },
            {
              "drug": "C1635969",
              "dosage": "5.4 mk/kg",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null
            }
          ],
          "procedures": [
            {
              "name": "C0344583",
              "date": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "21 days after first trastuzumab deruxtecan infusion, elevated troponin I levels reported (1910 pg/mL) without symptoms. ECG normal. Transthoracic echocardiography showed no repercussions on LVEF.",
        "timestamp": "2021-11",
        "clinical_data": {
          "labs": [
            {
              "test": "Troponin I",
              "value": "1910",
              "unit": "pg/mL",
              "flag": "abnormal",
              "timestamp": null
            }
          ],
          "imaging": [
            {
              "type": "Echocardiography",
              "body_part": "Heart",
              "modality": "Ultrasound",
              "finding": "no repercussions on LVEF",
              "impression": "normal",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Coronary angiography showed no significant lesions.",
        "timestamp": "2021-11",
        "clinical_data": {
          "imaging": [
            {
              "type": "Coronary angiography",
              "body_part": "Coronary arteries",
              "modality": "other",
              "finding": "no significant lesions"
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "Cardiac MRI showed signs of acute myocarditis according to Lake Louise Criteria (LLC), with apicolateral subepicardial late gadolinium enhancement (LGE) associated with local increase of native T1 (1200 msec; LLC-T1 >1000 msec; normal 950\u20131000 msec) and T2 (72 msec; LLC-T2 >55.9 msec; normal 40\u201350 msec).",
        "timestamp": "2021-11",
        "clinical_data": {
          "imaging": [
            {
              "type": "Cardiac MRI",
              "body_part": "Heart",
              "modality": "MRI",
              "finding": "Signs of acute myocarditis according to Lake Louise Criteria (LLC), with apicolateral subepicardial late gadolinium enhancement (LGE) associated with local increase of native T1 and T2",
              "impression": "Acute myocarditis",
              "date": null
            }
          ],
          "labs": [
            {
              "test": "T1",
              "value": "1200",
              "unit": "msec",
              "flag": "abnormal",
              "reference_range": "950\u20131000 msec",
              "timestamp": null
            },
            {
              "test": "T2",
              "value": "72",
              "unit": "msec",
              "flag": "abnormal",
              "reference_range": "40\u201350 msec",
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": "C0027057",
              "label": "Myocarditis",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 10,
        "content": "Right ventricular endomyocardial biopsy showed no lymphocytic infiltrates or other alterations. Serology and autoimmunity parameters were negative, with no epidemiologic context or symptoms of viral infection.",
        "timestamp": "2021-11",
        "clinical_data": {
          "procedures": [
            {
              "name": "Endomyocardial biopsy",
              "location": "Right ventricle",
              "outcome": "no lymphocytic infiltrates or other alterations"
            }
          ],
          "labs": [
            {
              "test": "Serology",
              "value": "negative"
            },
            {
              "test": "autoimmunity parameters",
              "value": "negative"
            }
          ],
          "HPI": [
            {
              "summary": "no epidemiologic context or symptoms of viral infection"
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 11,
        "content": "Trastuzumab deruxtecan treatment discontinued",
        "clinical_data": {}
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initiation of first-line treatment for lung adenocarcinoma.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0007138",
            "C0876370",
            "C4049449"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2019-12"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Stereotactic lung radiotherapy delivered to the left lung lobe.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "procedure",
          "timestamp": "2020-11"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Maintenance therapy with pemetrexed and pembrolizumab.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0972734",
            "C1663790"
          ],
          "change_type": "other",
          "target_domain": "medication",
          "timestamp": "2021-08"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Disease progression detected on CT scan.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging",
          "timestamp": "2021-08"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Enrollment in DESTINY-Lung02 study; consideration of trastuzumab deruxtecan as second-line therapy.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C4721549"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2021-08"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Initiation of trastuzumab deruxtecan treatment after cardiac evaluation.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1635969"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2021-10"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Elevated troponin I levels reported 21 days after first trastuzumab deruxtecan infusion.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [],
          "change_type": "escalation",
          "target_domain": "lab",
          "timestamp": "2021-11"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Coronary angiography performed, showing no significant lesions.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [],
          "change_type": "addition"
        }
      }
    }
  ]
}